Vers une hausse du marché des traitements de Parkinson

Decision Resources, Inc., one of the world’s leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the Parkinson’s disease (PD) market will grow steadily in the next ten years as populations age and polytherapy becomes the norm in both the early and more advanced stages of the disease. A new study entitled Parkinson’s Disease finds that the newer, more expensive therapies such as dopamine agonists will boost the number of PD patients taking polytherapy, thus increasing the overall drug market’s value. « Novel therapies designed to improve patients’ responses to levodopa will greatly expand the PD market over the next decade, » said Tricia Nagle, analyst at Decision Resources. « Also fueling this sector will be continued growth by current market leaders, including Novartis/Orion’s Comtan, GlaxoSmithKline’s Requip, and Pfizer/Boehringer Ingelheim’s Mirapex/Sifrol. Overall drug sales for PD in the major markets in 2012 will more than double 2002 sales. » About Parkinson’s Disease The chronic, progressive nature of PD and the fact that no currently available treatments slow or stop the disease’s progression make it an attractive target for drug development. Moreover, an ever-growing elderly population that will lead to a steadily increasing number of PD sufferers over the next